FR24C1010I1 - DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH - Google Patents
DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGHInfo
- Publication number
- FR24C1010I1 FR24C1010I1 FR24C1010C FR24C1010C FR24C1010I1 FR 24C1010 I1 FR24C1010 I1 FR 24C1010I1 FR 24C1010 C FR24C1010 C FR 24C1010C FR 24C1010 C FR24C1010 C FR 24C1010C FR 24C1010 I1 FR24C1010 I1 FR 24C1010I1
- Authority
- FR
- France
- Prior art keywords
- diaminopyrimidine
- cough
- treatment
- receptor modulators
- modulators
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100040479 P2X purinoceptor 2 Human genes 0.000 title 1
- 101710189968 P2X purinoceptor 2 Proteins 0.000 title 1
- 102100040460 P2X purinoceptor 3 Human genes 0.000 title 1
- 101710189970 P2X purinoceptor 3 Proteins 0.000 title 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562234584P | 2015-09-29 | 2015-09-29 | |
| US201662336381P | 2016-05-13 | 2016-05-13 | |
| PCT/US2016/053223 WO2017058645A1 (en) | 2015-09-29 | 2016-09-23 | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR24C1010I1 true FR24C1010I1 (en) | 2024-05-24 |
Family
ID=58424436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR24C1010C Active FR24C1010I1 (en) | 2015-09-29 | 2024-03-12 | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11260056B2 (en) |
| EP (2) | EP3355889B1 (en) |
| JP (1) | JP6877441B2 (en) |
| KR (1) | KR20180054843A (en) |
| AU (1) | AU2016330466B2 (en) |
| CA (1) | CA2998742C (en) |
| DK (1) | DK3355889T3 (en) |
| ES (1) | ES2942711T3 (en) |
| FI (2) | FI3355889T3 (en) |
| FR (1) | FR24C1010I1 (en) |
| HR (1) | HRP20230445T1 (en) |
| HU (2) | HUE061764T2 (en) |
| LT (1) | LT3355889T (en) |
| MX (1) | MX2018003893A (en) |
| NL (1) | NL301260I2 (en) |
| PL (1) | PL3355889T3 (en) |
| PT (1) | PT3355889T (en) |
| RS (1) | RS64155B1 (en) |
| SI (1) | SI3355889T1 (en) |
| WO (1) | WO2017058645A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019012340B1 (en) | 2016-12-20 | 2022-01-11 | Afferent Pharmaceuticals, Inc. | CRYSTALLINE CITRATE A FORM OF 5-(2,4-DIAMINO-PYRIMIDIN-5-ILOXY)-4-ISOPROPYL-2-METOXYBENZENENOSULFONAMIDE, AS WELL AS ITS PHARMACEUTICAL COMPOSITION AND USES |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| CA3100099A1 (en) * | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| CN113559104A (en) * | 2018-10-05 | 2021-10-29 | 盐野义制药株式会社 | Medicine for treating chronic cough |
| US20220211703A1 (en) * | 2019-04-30 | 2022-07-07 | Beijing Tide Pharmaceutical Co., Ltd. | Method for treating cough by using diaminopyrimidine compound |
| MX2021014116A (en) | 2019-05-31 | 2021-12-10 | Chiesi Farm Spa | Pyridopyrimidines derivatives as p2x3 inhibitors. |
| EP3976180A1 (en) | 2019-05-31 | 2022-04-06 | Chiesi Farmaceutici S.p.A. | Amino quinazoline derivatives as p2x3 inhibitors |
| BR112022004398A2 (en) | 2019-09-19 | 2022-05-31 | Shionogi & Co | 1,3,5-triazine derivative crystal or solvate thereof and method of producing the same |
| CN111635368B (en) * | 2020-06-12 | 2021-06-29 | 东莞市东阳光仿制药研发有限公司 | Preparation method of amine compound |
| CN116745284A (en) | 2020-11-27 | 2023-09-12 | 奇斯药制品公司 | Phthalazine derivatives as P2X3 inhibitors |
| US20230416233A1 (en) | 2020-11-27 | 2023-12-28 | Chiesi Farmaceutici S.P.A. | (aza)quinoline 4-amines derivatives as p2x3 inhibitors |
| MX2023005803A (en) | 2020-11-27 | 2023-05-29 | Chiesi Farm Spa | Amino quinazoline derivatives as p2x3 inhibitors. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1725540T5 (en) | 2004-03-05 | 2012-10-22 | Hoffmann La Roche | DIAMINOPYRIMIDINES AS P2X3 AND P2X2 / 3 ANTAGONISTS |
| US20060029548A1 (en) | 2004-07-22 | 2006-02-09 | Amir Pelleg | Methods of diagnosing, monitoring and treating pulmonary diseases |
| EP1924566B1 (en) | 2005-09-01 | 2016-01-13 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| CA2619919C (en) | 2005-09-01 | 2014-04-01 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| SI1924264T1 (en) | 2005-09-01 | 2013-12-31 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| EP1926716B1 (en) | 2005-09-01 | 2011-10-19 | F. Hoffmann-La Roche AG | Process for synthesis of aryloxy diaminopyrimidines |
| AU2007304280B2 (en) * | 2006-10-04 | 2013-01-31 | F. Hoffmann-La Roche Ag | Process for synthesis of phenoxy diaminopyrimidine derivatives |
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| MY195728A (en) | 2013-08-23 | 2023-02-07 | Afferent Pharmaceuticals Inc | Diaminopyrimidine P2x3 and P2x 2/3 Receptor Modulators for Treatment of Acute, Sub-Acute or Chronic Cough |
-
2016
- 2016-09-23 JP JP2018535821A patent/JP6877441B2/en active Active
- 2016-09-23 LT LTEPPCT/US2016/053223T patent/LT3355889T/en unknown
- 2016-09-23 WO PCT/US2016/053223 patent/WO2017058645A1/en active Application Filing
- 2016-09-23 RS RS20230321A patent/RS64155B1/en unknown
- 2016-09-23 HU HUE16852340A patent/HUE061764T2/en unknown
- 2016-09-23 HR HRP20230445TT patent/HRP20230445T1/en unknown
- 2016-09-23 SI SI201631686T patent/SI3355889T1/en unknown
- 2016-09-23 CA CA2998742A patent/CA2998742C/en active Active
- 2016-09-23 PL PL16852340.5T patent/PL3355889T3/en unknown
- 2016-09-23 DK DK16852340.5T patent/DK3355889T3/en active
- 2016-09-23 AU AU2016330466A patent/AU2016330466B2/en active Active
- 2016-09-23 PT PT168523405T patent/PT3355889T/en unknown
- 2016-09-23 MX MX2018003893A patent/MX2018003893A/en unknown
- 2016-09-23 KR KR1020187011747A patent/KR20180054843A/en not_active Application Discontinuation
- 2016-09-23 US US15/764,174 patent/US11260056B2/en active Active
- 2016-09-23 EP EP16852340.5A patent/EP3355889B1/en active Active
- 2016-09-23 ES ES16852340T patent/ES2942711T3/en active Active
- 2016-09-23 EP EP23155536.8A patent/EP4215182A1/en active Pending
- 2016-09-23 FI FIEP16852340.5T patent/FI3355889T3/en active
-
2022
- 2022-01-24 US US17/582,485 patent/US20220143015A1/en active Pending
-
2024
- 2024-03-04 NL NL301260C patent/NL301260I2/en unknown
- 2024-03-05 HU HUS2400004C patent/HUS2400004I1/en unknown
- 2024-03-12 FR FR24C1010C patent/FR24C1010I1/en active Active
- 2024-03-13 FI FIC20240006C patent/FIC20240006I1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11260056B2 (en) | 2022-03-01 |
| CA2998742C (en) | 2023-08-29 |
| HUS2400004I1 (en) | 2024-04-28 |
| RS64155B1 (en) | 2023-05-31 |
| EP3355889B1 (en) | 2023-02-15 |
| CA2998742A1 (en) | 2017-04-06 |
| HUE061764T2 (en) | 2023-08-28 |
| KR20180054843A (en) | 2018-05-24 |
| US20180280388A1 (en) | 2018-10-04 |
| WO2017058645A1 (en) | 2017-04-06 |
| SI3355889T1 (en) | 2023-07-31 |
| PT3355889T (en) | 2023-04-26 |
| EP3355889A1 (en) | 2018-08-08 |
| LT3355889T (en) | 2023-05-10 |
| ES2942711T3 (en) | 2023-06-06 |
| JP6877441B2 (en) | 2021-05-26 |
| DK3355889T3 (en) | 2023-05-15 |
| US20220143015A1 (en) | 2022-05-12 |
| FIC20240006I1 (en) | 2024-03-13 |
| PL3355889T3 (en) | 2023-05-22 |
| AU2016330466A1 (en) | 2018-03-29 |
| HRP20230445T1 (en) | 2023-07-21 |
| AU2016330466B2 (en) | 2021-01-28 |
| NL301260I2 (en) | 2024-03-25 |
| FI3355889T3 (en) | 2023-05-15 |
| EP3355889A4 (en) | 2019-05-22 |
| MX2018003893A (en) | 2018-06-22 |
| EP4215182A1 (en) | 2023-07-26 |
| JP2018529776A (en) | 2018-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR24C1010I1 (en) | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH | |
| DK3676316T3 (en) | LIQUID COMPOSITION INCLUDING BIOLOGICAL UNITS AND USES THEREOF | |
| DK3889145T3 (en) | 8-cyano-5-piperidino-quinolines as TLR7/8 antagonists and uses thereof for the treatment of immune diseases | |
| MA42819A (en) | METHODS FOR THE TREATMENT OF ARENAVIRIDAE AND CORONAVIRIDAE VIRAL INFECTIONS | |
| MA47688A (en) | USEFUL COMPOSITIONS IN THE TREATMENT OF SPINAL AMYOTROPHY | |
| ITUA20164498A1 (en) | METHOD AND APPARATUS FOR THE USE OF DRONES IN FIRE APPLICATIONS | |
| DK3481846T3 (en) | 11-SUBSTITUTED 24-HYDROXYSTEROLS FOR USE IN THE TREATMENT OF NMDA-RELATED CONDITIONS | |
| FR3032353B1 (en) | PHARMACEUTICAL COMPOSITION AND DEVICE FOR THE TREATMENT OF PAIN | |
| IL291029A (en) | Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use | |
| IL265648A (en) | P2x3 and/or p2x2/3 compounds and methods | |
| MA50233A (en) | MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY | |
| MA44762A (en) | SEMAGLUTIDE USED IN THE TREATMENT OF CARDIOVASCULAR DISEASES | |
| FR3036598B1 (en) | APPLICATION AND MASSAGE DEVICE | |
| DE112017006004A5 (en) | METHOD AND DEVICE FOR THE CARE OF FLOOR SURFACES AND UNKRAUTED DESCALING DEVICE | |
| DK3365329T3 (en) | NURR1: RXR ACTIVATING COMPOUNDS FOR CONTEMPORARY TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S SICKNESS | |
| MA49524A (en) | NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF DEPRESSION | |
| MA41120A (en) | COMPOSITIONS INCLUDING 15-HEPE AND METHODS OF TREATING OR PREVENTING FIBROSIS USING THEM | |
| MA49618A (en) | MPO INHIBITORS FOR USE IN MEDICINE | |
| IT201600130012A1 (en) | Composition for use in the treatment of disorders of the urogenital system | |
| MA52691A (en) | STATIN COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | |
| MA44660A (en) | (+) - AZASETRON INTENDED FOR USE IN THE TREATMENT OF EAR DISORDERS | |
| CY1119674T1 (en) | Alzheimer's Disease Treatment and Prevention (AD) | |
| IT201700111939A1 (en) | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF INFLAMMATORY STATES | |
| IT201600122310A1 (en) | Composition for use in the treatment of bowel disorders | |
| DK3634957T3 (en) | NMDA RECEPTOR MODULATORS, COMPOSITIONS INCLUDING THE SAME, AND THE USE OF THESE COMPOUNDS IN THE TREATMENT OF DISEASES COVERING THE CENTRAL NERVOUS SYSTEM |